Top of the morning to you, and a fine one it is. A shiny sun and a cool breeze are enveloping the Pharmalot campus, where the shortest person has left for summer work and the official mascots are, as always, ensconced in their favorite snoozing corners. As for us, we are diligently following the usual routine of foraging for interesting items and, of course, quaffing cups of stimulation. Feel free to join us or have a bottle of water, if you fancy. Meanwhile, here are some tidbits. Have a smashing day and please do keep in touch. We enjoy hearing secrets …
GSK is streamlining its research efforts, according to Pharmaphorum. The drug maker plans to allocate capital to priority areas, including HIV and respiratory and infectious diseases, as well as two potential areas of oncology and immuno-inflammation. But more than 30 preclinical and clinical programs will be stopped, partnered or divested, and the company is considering options for its rare diseases unit after a strategic review.
About the Author Reprints
